Which is more elusive, the pot of gold at the end of a rainbow or determining the most cost-effective triptan?
Culley
Eric J
EJ
DUR Clinical Pharmacy Specialist, Pittsburgh, PA 15222, USA. eric.culley@highmark.com
D003362:Cost-Benefit Analysis; D006801:Humans; D007211:Indoles / Q000008:administration & dosage* / Q000191:economics*; D015201:Meta-Analysis as Topic; D008881:Migraine Disorders / Q000188:drug therapy; D011759:Pyrrolidines / Q000008:administration & dosage* / Q000191:economics*; D012702:Serotonin Antagonists / Q000008:administration & dosage* / Q000191:economics*; D014363:Tryptamines; D014481:United States
D007211:Indoles; D011759:Pyrrolidines; D012702:Serotonin Antagonists; D014363:Tryptamines; C115647:eletriptan